• This record comes from PubMed

miR-9 is a tumor suppressor in pediatric AML with t(8;21)

. 2014 May ; 28 (5) : 1022-32. [epub] 20131125

Language English Country England, Great Britain Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid24270738

MicroRNAs (miRNAs) play a pivotal role in the regulation of hematopoiesis and development of leukemia. Great interest emerged in modulating miRNA expression for therapeutic purposes. In order to identify miRNAs, which specifically suppress leukemic growth of acute myeloid leukemia (AML) with t(8;21), inv(16) or mixed lineage leukemia (MLL) rearrangement by inducing differentiation, we conducted a miRNA expression profiling in a cohort of 90 cytogenetically characterized, de novo pediatric AML cases. Four miRNAs, specifically downregulated in MLL-rearranged, t(8;21) or inv(16) AMLs, were characterized by their tumor-suppressive properties in cell lines representing those respective cytogenetic groups. Among those, forced expression of miR-9 reduced leukemic growth and induced monocytic differentiation of t(8;21) AML cell lines in vitro and in vivo. The tumor-suppressive functions of miR-9 were specifically restricted to AML cell lines and primary leukemic blasts with t(8;21). On the other hand, these functions were not evident in AML blasts from patients with MLL rearrangements. We showed that miR-9 exerts its effects through the cooperation with let-7 to repress the oncogenic LIN28B/HMGA2 axis. Thus, miR-9 is a tumor suppressor-miR which acts in a stringent cell context-dependent manner.

See more in PubMed

Br J Haematol. 2012 Jul;158(2):283-285 PubMed

Oncogene. 2002 May 9;21(20):3190-8 PubMed

Genes Dev. 2010 Mar 1;24(5):478-90 PubMed

Nat Cell Biol. 2008 Aug;10(8):987-93 PubMed

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11511-6 PubMed

Nat Genet. 2007 Oct;39(10):1278-84 PubMed

Leukemia. 2005 Feb;19(2):245-52 PubMed

Leukemia. 2010 Feb;24(2):460-6 PubMed

Science. 2007 Dec 21;318(5858):1917-20 PubMed

Science. 2008 Apr 4;320(5872):97-100 PubMed

Leukemia. 2012 Nov;26(11):2310-6 PubMed

Science. 2012 Mar 9;335(6073):1195-200 PubMed

Nat Rev Genet. 2004 May;5(5):396-400 PubMed

Science. 2007 Mar 16;315(5818):1576-9 PubMed

Leukemia. 2013 Jan;27(1):100-6 PubMed

Br J Cancer. 1994 Dec;70(6):1047-52 PubMed

Cell. 2011 Nov 23;147(5):1066-79 PubMed

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5594-9 PubMed

Gene Ther. 2010 Mar;17(3):400-11 PubMed

Leukemia. 2013 Feb;27(2):344-52 PubMed

Blood. 2010 Jan 21;115(3):453-74 PubMed

RNA. 2008 Aug;14(8):1539-49 PubMed

Cell. 2005 Mar 11;120(5):635-47 PubMed

Blood. 2012 Oct 18;120(16):3187-205 PubMed

Leukemia. 2013 Apr;27(4):871-8 PubMed

J Cancer Res Clin Oncol. 2012 Apr;138(4):595-602 PubMed

Science. 2009 Nov 6;326(5954):867-71 PubMed

Blood. 2012 Mar 8;119(10):2314-24 PubMed

Genome Res. 2010 May;20(5):589-99 PubMed

Blood. 2008 May 15;111(10):5078-85 PubMed

Blood. 1999 Sep 1;94(5):1578-89 PubMed

Mol Cell Biol. 2003 Dec;23(24):9104-16 PubMed

Mol Cell. 2008 Oct 24;32(2):276-84 PubMed

Trends Mol Med. 2008 Sep;14(9):400-9 PubMed

Ann Hematol. 2012 Nov;91(11):1673-84 PubMed

Blood. 2006 Nov 15;108(10):3520-9 PubMed

Haematologica. 2011 Oct;96(10):1478-87 PubMed

Pediatr Blood Cancer. 2012 May;58(5):715-21 PubMed

Nat Methods. 2009 Dec;6(12):897-903 PubMed

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15443-8 PubMed

Blood. 2009 Apr 2;113(14):3314-22 PubMed

RNA. 2008 Jun;14(6):1012-7 PubMed

Nat Genet. 1995 Aug;10(4):436-44 PubMed

Cell. 2005 Jan 14;120(1):15-20 PubMed

Genes Dev. 2010 Aug 1;24(15):1659-72 PubMed

Genes Dev. 2007 May 1;21(9):1025-30 PubMed

Ann Hematol. 2001 Jul;80(7):417-22 PubMed

Leukemia. 2014 Mar;28(3):577-88 PubMed

Nucleic Acids Res. 2009 Jan;37(Database issue):D105-10 PubMed

J Clin Oncol. 2010 Dec 20;28(36):5257-64 PubMed

Br J Haematol. 2012 Apr;157(2):270-4 PubMed

Stat Appl Genet Mol Biol. 2004;3:Article3 PubMed

Find record

Citation metrics

Archiving options